Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes

Bibliography

• AUGUSTYNS K, VAN DER VEKEN P,SENTEN K, HAEMERS A: Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes. Expert Opin. Ther. Patents (2003) 13:499–510.
   Web of Science ®Google Scholar
• AUGUSTYNS K, BAL G, THONUS Get al.: The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors. Curr. Med. Chem. (1999) 6:311–327.
   Google Scholar
• AUGUSTYNS K, VAN DER VEKEN P, SENTEN K, HAEMERS k The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. Curr. Med. Chem. (2005) 12:971–998.
   PubMed Web of Science ®Google Scholar
• ••A recent review giving an exhaustiveoverview of the properties of DPP IV and its inhibitors.
   Google Scholar
• LAMBEIR AM, DURINX C, SCHARPE S, DE MEESTER I: Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. (2003) 40:209–294.
   PubMed Web of Science ®Google Scholar
• AHREN B: Inhibition of dipeptidyl peptidase-4 (DPP4) - A novel approach to treat Type 2 diabetes. Curr. Enzyme Inhib. (2005) 1:65–73.
   Google Scholar
• •A recent review describing the predinical and clinical proof of concept of DPP IV inhibitors for the treatment of Type 2 diabetes.
   Google Scholar
• DEACON CF: Therapeutic strategies based on glucagon-like peptide 1. Diabetes (2004) 53:2181–2189.
   PubMed Web of Science ®Google Scholar
• DEACON CF, AHREN B, HOLST JJ: Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opin. Investig Drugs (2004) 13:1091–1102.
   Google Scholar
• HOLST JJ, DEACON CF: Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of Type 2 diabetes mellitus. Curr. Opin. Pharmacol. (2004) 4:589–596.
   PubMed Web of Science ®Google Scholar
• HOLST JJ: Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP IV inhibitors. Expert Opin. Emerg Drugs (2004) 9:155–166.
   PubMedGoogle Scholar
• WEBER AE: Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J. Med. Chem. (2004) 47:4135–4141.
   PubMed Web of Science ®Google Scholar
• NAUCK Mk STOCKMANN F, EBERT R, CREUTZFELDT W: Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia (1986) 29:46–52.
   PubMed Web of Science ®Google Scholar
• NAUCK Mk KLEINE N, ORSKOV C et al.: Normalization of fasting hyperglycemia by exogenous GLP-1 (7–36 amide) in Type 2 diabetic patients. Diabetologia (2005) 36:741–744.
   Google Scholar
• PAULY RP, DEMUTH HU, ROSCHE F et al.: Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. Metabolism (1999) 48:385–389.
   PubMed Web of Science ®Google Scholar
• PEDERSON RA, WHITE HA, SCHLENZIG D et al.: Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes (1998) 47:1253–1258.
   PubMed Web of Science ®Google Scholar
• POSPISILIK JA, STAFFORD SG, DEMUTH HU et al.: Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and 0-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes (2002) 51:943–950.
   PubMed Web of Science ®Google Scholar
• POSPISILIK JA, STAFFORD SG, DEMUTH HU, MCINTOSH CH, PEDERSON RA: Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes (2002) 51:2677–2683.
   PubMed Web of Science ®Google Scholar
• POSPISILIK JA, MARTIN J, DOTY T et al.: Dipeptidyl peptidase IV inhibitor treatment stimulates 0-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes (2003) 52:741–750.
   PubMed Web of Science ®Google Scholar
• DEACON CF, HUGHES TE, HOLST JJ: Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes (1998) 47:764–769.
   PubMed Web of Science ®Google Scholar
• DEACON CF, DANIELSEN P, KLARSKOV L, OLESEN M, HOLST JJ: Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes (2001) 50:1588–1597.
   PubMed Web of Science ®Google Scholar
• AHREN B, HOLST JJ, MARTENSSON H, BALKAN B: Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur. J. Pharmacol. (2000) 404:239–245.
   PubMed Web of Science ®Google Scholar
• SUDRE B, BROQUA P, WHITE RB et al.:Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes (2002) 51:1461–1469.
   PubMed Web of Science ®Google Scholar
• BALKAN B, KWASNIK L, MISERENDINO R, HOLST JJ, LI X: Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia (1999) 42:1324–1331.
   PubMed Web of Science ®Google Scholar
• AHREN B, SIMONSSON E, LARSSON H et al.: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in Type 2 diabetes. Diabetes Care (2002) 25:869–875.
   PubMed Web of Science ®Google Scholar
• DEACON CF, WAMBERG S, BIE P, HUGHES TE, HOLST JJ: Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J. EndocrinoL (2002) 172:355–362.
   PubMed Web of Science ®Google Scholar
• REIMER MK, HOLST JJ, AHREN B: Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur. EndocrinoL (2002) 146:717–727.
   PubMed Web of Science ®Google Scholar
• MITANI H, TAKIMOTO M, HUGHES TE, KIMURA M: Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity. Jpn. J. PharmacoL (2002) 88:442–450.
   PubMedGoogle Scholar
• MITANI H, TAKIMOTO M, KIMURA M: Dipeptidyl peptidase IV inhibitor NVP-DPP728 ameliorates early insulin response and glucose tolerance in aged rats but not in aged Fischer 344 rats lacking its enzyme activity. Jpn. PharmacoL (2002) 88:451–458.
   PubMedGoogle Scholar
• LANKAS G, LETTING B, ROY RS et al.: Inhibition of DPP8/9 results in toxicity in preclinical species : potential importance of selective dipeptidyl peptidase IV inhibition for the treatment of Type 2 diabetes mellitus. Diabetes (2004) 53:A2,7-OR.
   Google Scholar
• HUGHES TE, MONE MD, RUSSELL ME, WELDON SC, VILLHAUER EB: NVP-DPP728 (14024(5-cyanopyridin-2-yfiaminolethyllaminolacetyil-2-cyano-(S)-pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV Biochemistry (1999) 38:11597–11603.
   Google Scholar
• ENGEL M, HOFFMANN T, WAGNER L et aL: The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc. Nail. Acad. Sc. USA (2003) 100:5063–5068.
   PubMed Web of Science ®Google Scholar
• FLENTKE GR, MUNOZ E, HUBER BT et al.: Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc. Natl. Acad. Sci. USA (1991) 88:1556–1559.
   PubMed Web of Science ®Google Scholar
• BELYAEV A, ZHANG X, AUGUSTYNS K et al.: Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors. J. Med. Chem. (1999) 42:1041–1052.
   PubMedGoogle Scholar
• MAGNIN DR, ROBL JA, SULSKY RB et al.: Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of a-aminoacyl-l-eis-4,5-methanoprolinenitrile-based inhibitors. J. Med. Chem. (2004) 47:2587–2598.
   PubMed Web of Science ®Google Scholar
• ••Describes the discovery and properties ofBMS-477118.
   Google Scholar
• VAN DER VEKEN P, SENTEN K, KERTESZ I et al.: Fluoro-olefins as peptidomimetic inhibitors of dipeptidyl peptidases. J. Med. Chem. (2005) 48:1768–1780.
   Google Scholar
• ASHWORTH D, ATRASH B, BAKER GR et al.: 2-Cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV Bioorg. Med. Chem. Lem (1996) 6:1163–1166.
   Web of Science ®Google Scholar
• PARMEE ER, HE J, MASTRACCHIO A et al.: 4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:43–46.
   PubMed Web of Science ®Google Scholar
• ASHTON WT, DONG H, SISCO RM et al.: Diastereoselective synthesis and configuration-dependent activity of (3-substituted-cycloalkyfiglycine pyrrolidides and thiazolidides as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lem. (2004) 14:859–863.
   PubMedGoogle Scholar
• AUGUSTYNS KJL, LAMBEIR AM, BORLOO M et al.: Pyrrolidides: synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV Eur. Med. Chem. (1997) 32:301–309.
   Google Scholar
• CALD WELL CG, CHEN P, HE Jet al.: Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lem. (2004) 14:1265–1268.
   Google Scholar
• XU S, ZHU B, TEFFERA Y et aL: Metabolic activation of fluoropyrrolidine dipeptidyl peptidase-IV inhibitors by rat liver microsomes. Drug. Metab. Dispos. (2005) 33:121–130.
   PubMed Web of Science ®Google Scholar
• XU J, WET L, MATHVINK R et aL: Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors. Bioorg Med. Chem. Lem. (2005) 15:2533–2536.
   PubMed Web of Science ®Google Scholar
• MASTRACCHIO A, PARMEE ER, LETTING B et al.: Heterocycle fused cyclohexylglycine derivatives as novel dipeptidyl peptidase-IV inhibitors. Heterocycles (2004) 62:203–206.
   Google Scholar
• EDMONDSON SD, MASTRACCHIO A, DUFFY JL et aL: Discovery of potent and selective orally bioavailable 0-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lem (2005) 15 online.
   Google Scholar
• XU J, OK HO, GONZALEZ EJ et ell.: Discovery of potent and selective 0-homophenylalanine based dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:4759–4762.
   Google Scholar
• EDMONDSON SD, MASTRACCHIO A, BECONI M et aL: Potent and selective proline derived dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lem (2004) 14:5151–5155.
   PubMedGoogle Scholar
• BROCKUNIER LL, HE J, COLWELL LF et al.: Substituted piperazines as novel dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lem (2004) 14:4763–4766.
   PubMedGoogle Scholar
• KIM D, WANG L, BECONI M et aL: (2R)-4-oxo-4-l3-(trifluoromethyl)-5,6- dihydro [1,2,4] triazolopyrazin-7(8H)-yll -1-(2,4,5-trifluorophenyfibutan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes. J. Med. Chem. (2005) 48:141–151.
   PubMed Web of Science ®Google Scholar
• •Describes the discovery and properties of MK-0431.
   Google Scholar
• ASHTON WT, SISCO RM, DONG H et al.: Dipeptidyl peptidase IV inhibitors derived from 0-aminoacylpiperidines bearing a fused thiazole, oxazole, isoxazole or pyrazole. Bioorg. Med. Chem. Lett. (2005) 15:2253–2258.
   PubMedGoogle Scholar
• FUKUSHIMA H, HIRATATE A, TAKAHASHI M et al.: Synthesis and structure-activity relationships of potent 3-or 4-substituted-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. (2004) 12:6053–6061.
   PubMedGoogle Scholar
• HAFFNER C: 4-Fluorocyanopyrrolidinesas inhibitors of dipeptidyl peptidase IV (DPP IV). 228th ACS Meeting Philadelphia, PA. (2004). Abstract 205.
   Google Scholar
• AHN JH, KIM HM, JUNG SH et aL: Synthesis and DP-IV inhibition of cyano-pyrazoline derivatives as potent anti-diabetic agents. Bioorg. Med. Chem. Lett. (2004) 14:4461–4465.
   PubMed Web of Science ®Google Scholar
• AHN JH, KIM JA, KIM HM et ell.: Synthesis and evaluation of pyrazolidine derivatives as dipeptidyl peptidase IV (DPP IV) inhibitors. Bioorg. Med. Chem. Lett. (2005) 15:1337–1340.
   Google Scholar
• CHEON HG, KIM SS, KIM S et al: Inhibition of dipeptidyl peptidase IV by novel inhibitors with pyrazolidine scaffold. Biochem. Pharmacol (2005) online.
   Google Scholar
• VILLHAUER EB, BRINKMAN JA, NADERI GB et al.: 1-12-1(5-Cyanopyridin-2-yDaminolethylaminolacety1-2-(5)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. (2002) 45:2362–2365.
   PubMed Web of Science ®Google Scholar
• •Describes the discovery and properties of NVP-DPP728.
   Google Scholar
• VILLHAUER EB, BRINKMAN JA, NADERI GB et al.: 1-[[(3-hy cfroxy -1-adamantyDamino]acety1]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. (2003) 46:2774–2789.
   PubMed Web of Science ®Google Scholar
• ••Describes the discovery and properties ofNVP-LAF237.
   Google Scholar
• TAKASAKI K, IWASE M, NAKAJIMA T et al.: K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent. Eur. J. Pharmacol. (2004) 486:335–342.
   PubMed Web of Science ®Google Scholar
• TAKASAKI K, TAKADA H, NAKAJIMA T et al.: Involvement of the active metabolites in the inhibitory activity of K579 on rat plasma dipeptidyl peptidase IV. Eur. j PharmacoL (2004) 505:237–241.
   PubMedGoogle Scholar
• TAKASAKI K, NAKAJIMA T, UENO K, NOMOTO Y, HIGO K: Effects of combination treatment with dipeptidyl peptidase IV inhibitor and sulfonylurea on glucose levels in rats. J. PharmacoL Sci. (2004) 95:291–293.
   PubMed Web of Science ®Google Scholar
• SAKASHITA H, KITAJIMA H, NAKAMURA M, AKAHOSHI F, HAYASHI Y: 1-((S)-y-substituted proly1)-(S)-2-cyanopyrrolidine as a novel series of highly potent DPP IV inhibitors. Bioorg. Med. Chem. Lett. (2005) 15:2441–2445.
   PubMedGoogle Scholar
• KANSTRUP AB, BRANNER S, CARR RD et al.: Understanding the structure of human DPP IV and its specificity. 3rd International Protease Meeting. Nagoya, Japan. (2003). Poster.
   Google Scholar
• KANSTRUP AB, BOWLER AN, CARR RD et al.: 13-amino acid based inhibitors of DPP IV International Symposium on Medicinal Chemistry. Copenhagen, Denmark. (2004). Poster.
   Google Scholar
• HAMANN LG: Design, synthesis and pharmacology of BMS-477118: a long acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes. 228th ACS Meeting. Philadelphia, PA, USA (2004). OR–207.
   Google Scholar
• ROBL JA: Design, synthesis, and pharmacology of BMS-477118: along-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes. 18th International Symposium on Medicinal Chemistry Copenhagen, Denmark. (2004). Oral communication.
   Google Scholar
• ZHAO K, LIM DS, FUNAKI T, WELCH JT: Inhibition of dipeptidyl peptidase IV (DPP IV) by 2-(2-amino-1-fluoro-propylidene)-cyclopentanecarbonitrile, a fluoroolefin containing peptidomimetic. Bioorg. Med. Chem. (2003) 11:207–215.
   PubMedGoogle Scholar
• VAN DER VEKEN P, KERTESZ I, SENTEN K, HAEMERS A, AUGUSTYNS K: Synthesis of()- and (Z)-fluoro-olefin analogues of potent dipeptidyl peptidase IV inhibitors. Tetrahedron Lett. (2003) 44:6231–6234.
   Google Scholar
• FERRARIS D, KO YS, CALVIN D et al: Ketopyrrolidines and ketoazetidines as potent dipeptidyl peptidase IV (DPP IV) inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:5579–5583.
   PubMedGoogle Scholar
• KANSTRUP AB, BJELKE JR, BOWLER AN et al.: Design, synthesis, and biological evaluation of a series of potent xanthine-based inhibitors of the enzyme DPP IV. 2nd International Conference on Dipeptidyl Aminopcptidases. Magdeburg, Germany. (2005). Poster.
   Google Scholar
• PETERS JU, WEBER S, KRITTER S et al.: Aminomethylpyrimidines as novel DPP IV inhibitors: a 10(5)-fold activity increase by optimization of aromatic substituents. Bioorg Med. Chem. Lett. (2004) 14:1491–1493.
   PubMed Web of Science ®Google Scholar
• PETERS JU, HUNZIKER D, FISCHER H et al.: An aminomethylpyrimidine DPP IV inhibitor with improved properties. Bioorg Med. Chem. Lett. (2004) 14:3575–3578.
   PubMed Web of Science ®Google Scholar
• PETERS JU, WEBER S, KRITTER S et al.: Aminomethylpyridines as DPP IV inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:3579–3580.
   PubMed Web of Science ®Google Scholar
• AKIYAMA T, ABE M, HARADA S et al.: Sulphostin, a potent inhibitor for dipeptidyl peptidase IV from Streptomyces sp. MK251-43F3. J. Antibiot. (Tokyo) (2001) 54:744–746.
   Google Scholar
• ABE M, AKIYAMA T, NAKAMURA H et al.: First synthesis and determination of the absolute configuration of sulphostin, a novel inhibitor of dipeptidyl peptidase IV J. Nat. Prod. (2004) 67:999–1004.
   PubMedGoogle Scholar
• ABE M, AKIYAMA T, UMEZAWA Y et al.: Synthesis and biological activity of sulphostin analogues, novel dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. (2005) 13:785–797.
   PubMedGoogle Scholar
• ABE M, ABE F, NISHIMURA C et al.: Sulphostin, a novel inhibitor of dipeptidyl peptidase IV (DPP IV) that stimulates hematopoiesis in mice. J. Antibiot. (Tokyo) (2005) 58:111–117.
   PubMedGoogle Scholar
• JONES B, ADAMS S, MILLER GT et al: Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies. Blood (2003) 102:1641–1648.
   PubMed Web of Science ®Google Scholar
• CHEN WT, KELLY T: Seprase complexes in cellular invasiveness. Cancer Metastasis Rev. (2003) 22:259–269.
   PubMed Web of Science ®Google Scholar
• KELLY T: Fibroblast activation protein-a and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resistance Updates (2005) 8:51–58.
   PubMed Web of Science ®Google Scholar
• CHENG JD, DUNBRACK RL, VALIANOU M et al.: Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. (2002) 62:4767–4772.
   PubMed Web of Science ®Google Scholar
• GOODMAN JD, ROZYPAL TL, KELLY T: Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells. Clin. Exp. Metastasis (2003) 20:459–470.
   Google Scholar
• HUANG Y, WANG S, KELLY T: Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res. (2004) 64:2712–2716.
   PubMed Web of Science ®Google Scholar
• AIMES RT, ZIJLSTRA A. HOOPER JD et al: Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb. Haemost. (2003) 89:561–572.
   PubMed Web of Science ®Google Scholar
• CHENG JD, VALIANOU M, CANUTESCU AA et al.: Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol. Cancer Ther. (2005) 4:351–360.
   PubMed Web of Science ®Google Scholar
• RAMIREZ-MONTAGUT T, BLACHERE NE, SVIDERSKAYA EV et al.: FAPa, a surface peptidase expressed during wound healing, is a tumor suppressor. Oncogene (2004) 23:5435–5446.
   PubMed Web of Science ®Google Scholar
• COLLINS PJ, MCMAHON G, O'BRIEN P, O'CONNOR B: Purification, identification and characterisation of seprase from bovine serum. Int. J. Biochem. Cell. Biol. (2004) 36:2320–2333.
   PubMed Web of Science ®Google Scholar
• LAI JH, LIU Y, MAW HH et ell.: Investigation of exo- and endopeptidase activity of fibroblast activation protein inhibitors. 2nd International Conference on Dipeptidyl Aminopeptidases. Magdeburg, Germany. (2005). Poster A60.
   Google Scholar
• AERTGEERTS K, LEVIN I, SHI Let al.: Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein-a. J. Biol. Chem. (2005) 280:19441–19444.
   Google Scholar
• ADAMS S, MILLER GT, JESSON MI et al.: PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. (2004) 64:5471–5480.
   PubMed Web of Science ®Google Scholar
• MCINTYRE JA, CASTANER J: Talabostat . Oncolytic, hematopoietic agent, dipeptidyl-peptidase IV (CD26) inhibitor, fibroblast activation protein inhibitor. Drugs Fut. (2004) 29:882–886.
   Google Scholar
• CHIRAVURI M, SCHMITZ T, YARDLEY K et al.: A novel apoptotic pathway in quiescent lymphocytes identified by inhibition of a post-proline cleaving aminodipeptidase: a candidate target protease, quiescent cell proline dipeptidase. j Immunol (1999) 163:3092–3099.
   PubMedGoogle Scholar
• CHEN T, AJAMI K, MCCAUGHAN GW, GORRELL MD, ABBOTT CA: Dipeptidyl peptidase IV gene family. The DPIV family. Adv. Exp. Med. Biol. (2003) 524:79–86.
   PubMedGoogle Scholar
• ABBOTT CA, YU DM: WOOLLATT E et al.: Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur. j Biochem. (2000) 267:6140–6150.
   Google Scholar
• CHEN YS, CHIEN CH, GOPARAJU CM et al.: Purification and characterization of human prolyl dipeptidase DPP8 in Sf9 insect cells. Protein Expr. Purzf (2004) 35:142–146.
   PubMedGoogle Scholar
• OLSEN C, WAGTMANN N: Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV. Gene (2002) 299:185–193.
   PubMed Web of Science ®Google Scholar
• QI SY, RI WERE PJ, TROJNAR J, JUNIEN JL, AKINSANYA KO: Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases. Biochem. J. (2003) 373:179–189.
   PubMedGoogle Scholar
• AJAMI K, ABBOTT CA, MCCAUGHAN GW, GORRELL MD: Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPI V-likepeptidase activity. Biochim. Biophys. Acta (2004) 1679:18–28.
   PubMed Web of Science ®Google Scholar
• LEITING B, NICHOLS E, BIFTU T et al.: Inhibition of dipeptidyl peptidase IV does not attenuate T cell activation in vitro. Diabetes (2004) 53:A2,6-OR.
   Google Scholar
• JIAANG WT, CHEN YS, HSU T et al.: Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg Med. Chem. Lett. (2005) 15:687–691.
   PubMed Web of Science ®Google Scholar
• LEITING B, PRYOR KD, WU JK et al.:Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem. J. (2003) 371:525–532.
   PubMed Web of Science ®Google Scholar
• MAES MB, LAMBEIR AM, GILANY K et al.: Kinetic investigation of human dipeptidyl peptidase II (DPP II)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7). Biochem. J. (2005) 386:315–324.
   PubMed Web of Science ®Google Scholar
• UNDERWOOD R, CHIRAVURI M, LEE H et al.: Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. j Biol. Chem. (1999) 274:34053–34058.
   PubMed Web of Science ®Google Scholar
• CHIRAVURI M, LEE H, MATHIEU SL, HUBER BT: Homodimerization via a leucine zipper motif is required for enzymatic activity of quiescent cell proline dipeptidase. J. Biol Chem. (2000) 275:26994–26999.
   PubMedGoogle Scholar
• CHIRAVURI M, AGARRABERES F, MATHIEU SL, LEE H, HUBER BT: Vesicular localization and characterization of a novel post-proline-cleaving aminodipeptidase, quiescent cell proline dipeptidase. j Immunol (2000) 165:5695–5702.
   PubMed Web of Science ®Google Scholar
• CHIRAVURI M, HUBER BT: Aminodipeptidase inhibitor-induced cell death in quiescent lymphocytes: a review. Apoptosis (2000) 5:319–322.
   PubMedGoogle Scholar
• SENTEN K, VAN DER VEKEN P, BAL G et al.: Development of potent and selective dipeptidyl peptidase II inhibitors. Bioorg. Med. Chem. Lett. (2002) 12:2825–2828.
   Google Scholar
• SENTEN K, VAN DER VEKEN P, DE MEESTER I et al.: Design, synthesis, and SAP. of potent and selective dipeptide-derived inhibitors for dipeptidyl peptidases. J. Med. Chem. (2003) 46:5005–5014.
   Google Scholar
• SENTEN K, VAN DER VEKEN P, DE MEESTER I et al.: y-Amino-substituted analogues of 149–2,4-diaminobutanoyllpiperidine as highly potent and selective dipeptidyl peptidase II inhibitors. J. Med. Chem. (2004) 47:2906–2916.
   Google Scholar
• SENTEN K, DANIELS L, VAN DER VEKEN P et al.: Rapid parallel synthesis of dipeptide diphenyl phosphonate esters as inhibitors of dipeptidyl peptidases. J. Comb. Chem. (2003) 5:336–344.
   Google Scholar
• AHREN B, LANDIN-OLSSON M, JANSSON PA et al.: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in Type 2 diabetes./ Clin. Endocrinol Metab. (2004) 89:2078–2084.
   Google Scholar
• AHREN B, GOMIS R, STANDL E, MILLS D, SCHWEIZER A: 12- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with Type 2 diabetes. Diabetes Care (2004) 27:2874-2880. First report on the long term efficacy of a DPP W inhibitor (NVP-LAF237) for the treatment of Type 2 diabetes.
   Google Scholar
• SCOTT R, HERMAN G, ZHAO P et al.: Twelve-week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP IV) inhibitor, in the treatment of Type 2 diabetes (T2D). 65th American Diabetes Association Annual Meeting. San Diego, USA. (2005). 41-0R.
   Google Scholar
• WEBER AE, KIM D, BECONI M et al.: MK-0431 is a potent, selective, dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes. 63rd American Diabetes Association Annual Meeting. Orlando, FL, USA (2004). 633–P.
   Google Scholar